What is Sonoma Pharmaceuticals, Inc.'s earnings per share (EPS)?

Sonoma Pharmaceuticals, Inc. (SNOA) reported diluted earnings per share of -$1.89 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sonoma Pharmaceuticals, Inc. (SNOA) Financials

SNOA

Trailing 12 months to June 30, 2026

Revenue $21.9M +47.0% YoY

Net Income $914K +1066.9% YoY

EPS (Diluted) -$1.89 FY2026 annual

Free Cash Flow -$2.7M -93.5% YoY

Market Cap $5.7M as of Oct 13, 2026

Price / Sales 0.3x on $21.9M revenue, trailing 12 months to June 30, 2026

Price / Earnings 6.2x on $914K net income, trailing 12 months to June 30, 2026

Price / Book 0.9x on $6.6M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SNOA SEC filings page.

Sonoma Pharmaceuticals, Inc. (SNOA) reported $21.9M in revenue over the twelve months to Jun 30, 2026, up 47.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SNOA FY2026 2026-10-03

FY2026 growth improved gross economics, but the business still consumed cash and relied on a progressively thinner equity cushion.

In FY2026, near break-even net income of $3K coexisted with an operating loss of $2.5M. Operating cash flow was -$3.9M after -$88K in FY2025, so reported earnings did not translate into cash generation.

Gross margin stability around 38% alongside operating-margin improvement from -26.0% to -12.6% indicates fixed-cost absorption, not a fundamental change in product economics. Growth narrowed the operating deficit, but FY2026 still carried SG&A of $7.6M and R&D of $2.3M.

Liabilities reached $10.9M while equity fell to $3.1M in FY2026, making the balance sheet more liability-funded. Debt-to-equity rose to 3.5x, and the reported liquidity measure equaled 7.3 months of the latest annual operating outflow, indicating less financial cushion even without long-term debt reported.

Financial Health Signals

Financial Health Score 40/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Sonoma Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Sonoma Pharmaceuticals, Inc. has an operating margin of -12.6%, meaning the company loses $13 on every $100 of revenue. This results in a profitability score of 26/100. This is up from -26.0% the prior year.

Growth

Sonoma Pharmaceuticals, Inc.'s revenue surged 36.7% year-over-year to $19.5M, reflecting rapid business expansion. This strong growth earns a score of 85/100.

Leverage

Sonoma Pharmaceuticals, Inc. has elevated debt relative to equity (D/E of 3.51), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 18/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.50, Sonoma Pharmaceuticals, Inc. holds $2.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 71/100.

Cash Flow

Sonoma Pharmaceuticals, Inc.'s operations used $3.9M of cash, and capex of $192K added to the outflow, for a free cash flow shortfall of $4.1M. This results in a cash flow score of 10/100.

Returns

Sonoma Pharmaceuticals, Inc.'s ROE of 0.1% shows moderate profitability relative to equity, earning a score of 31/100. This is unchanged from the prior year.

Altman Z-Score Distress

-18.40

Sonoma Pharmaceuticals, Inc. scores -18.40, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.7M) relative to total liabilities ($10.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Sonoma Pharmaceuticals, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Sonoma Pharmaceuticals, Inc. reported $3K of net income while operations used $3.9M of cash. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.4M

YoY+59.6%

QoQ+15.2%

5Y CAGR+11.7%

10Y CAGR+9.3%

Sonoma Pharmaceuticals, Inc. generated $6.4M in revenue in Q1 2027. This represents an increase of 59.6% from the same quarter a year earlier. Against the prior quarter it is up 15.2%.

EBITDA

-$8K

YoY+99.2%

QoQ+97.5%

Sonoma Pharmaceuticals, Inc.'s EBITDA was -$8K in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 99.2% from the same quarter a year earlier. Against the prior quarter it is up 97.5%.

Net Income

-$330K

YoY+73.4%

QoQ-112.7%

Sonoma Pharmaceuticals, Inc. reported -$330K in net income in Q1 2027. This represents an increase of 73.4% from the same quarter a year earlier. Against the prior quarter it is down 112.7%.

EPS (Diluted)

-$0.09

QoQ+72.7%

Sonoma Pharmaceuticals, Inc. earned -$0.09 per diluted share (EPS) in Q1 2027. Against the prior quarter it is up 72.7%.

Cash & Balance Sheet

Free Cash Flow

-$651K

YoY+69.3%

QoQ-18.8%

Sonoma Pharmaceuticals, Inc. recorded an outflow of $651K in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents an increase of 69.3% from the same quarter a year earlier. Against the prior quarter it is down 18.8%.

Cash & Debt

$5.3M

YoY+48.1%

QoQ+122.5%

5Y CAGR+13.7%

10Y CAGR+0.7%

Sonoma Pharmaceuticals, Inc. held $5.3M in cash as of Q1 2027; long-term debt is not reported for that period.

Shares Outstanding

QoQ+0.1%

5Y CAGR+18.0%

10Y CAGR+1.3%

Sonoma Pharmaceuticals, Inc. had 5M shares outstanding in Q1 2027. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

40.2%

YoY+3.8pp

QoQ+1.0pp

5Y change+0.8pp

10Y change+3.0pp

Sonoma Pharmaceuticals, Inc.'s gross margin was 40.2% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is up 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.

Operating Margin

-0.6%

YoY+26.7pp

QoQ+5.7pp

5Y change+23.9pp

Sonoma Pharmaceuticals, Inc.'s operating margin was -0.6% in Q1 2027, reflecting core business profitability. This is up 26.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.7 percentage points.

Net Margin

-5.1%

YoY+25.8pp

QoQ-51.9pp

5Y change+24.6pp

10Y change+92.2pp

Sonoma Pharmaceuticals, Inc.'s net profit margin was -5.1% in Q1 2027, showing the share of revenue converted to profit. This is up 25.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 51.9 percentage points.

Return on Equity

-5.0%

YoY+25.6pp

QoQ-88.9pp

5Y change+18.8pp

10Y change+28.1pp

Sonoma Pharmaceuticals, Inc.'s ROE was -5.0% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 25.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 88.9 percentage points.

Capital Allocation

R&D Spending

$597K

YoY+0.5%

QoQ+9.5%

5Y CAGR+48.0%

10Y CAGR+5.2%

Sonoma Pharmaceuticals, Inc. invested $597K in research and development in Q1 2027. This represents an increase of 0.5% from the same quarter a year earlier. Against the prior quarter it is up 9.5%.

Capital Expenditures

$2K

YoY-98.1%

QoQ-93.1%

5Y CAGR-47.3%

10Y CAGR-17.7%

Sonoma Pharmaceuticals, Inc. invested $2K in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 98.1% from the same quarter a year earlier. Against the prior quarter it is down 93.1%.

Share Buybacks

Not reported for Q1 2027.

SNOA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SNOA quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$21.9M	$19.5M+36.7%	$14.3M+12.2%	$12.7M-4.0%	$13.3M+5.1%	$12.6M-32.2%	$18.6M+3.9%	$17.9M-5.5%	$19.0M+13.9%	$16.7M+29.9%	$12.8M+36.9%	$9.4M-32.4%	$13.9M+1.4%	$13.7M-11.5%	$15.5M+21.2%	$12.7M
Cost of Revenue	$13.4M	$12.1M+37.3%	$8.8M+10.4%	$8.0M-9.2%	$8.8M+1.9%	$8.6M-28.5%	$12.1M+23.1%	$9.8M-2.8%	$10.1M+7.9%	$9.3M+30.6%	$7.2M+6.5%	$6.7M+2.4%	$6.6M+24.6%	$5.3M+11.9%	$4.7M+16.8%	$4.0M
Gross Profit	$8.5M	$7.4M+35.7%	$5.5M+15.2%	$4.7M+6.0%	$4.5M+12.1%	$4.0M-39.1%	$6.6M-19.2%	$8.1M-8.5%	$8.9M+21.5%	$7.3M+29.0%	$5.7M+114.0%	$2.6M-63.7%	$7.3M-13.2%	$8.4M-21.8%	$10.7M+23.3%	$8.7M
R&D Expenses	$2.3M	$2.3M+25.2%	$1.8M-3.0%	$1.9M+803.9%	$207K+65.6%	$125K-77.5%	$555K-58.6%	$1.3M-11.8%	$1.5M-3.6%	$1.6M-0.1%	$1.6M-12.7%	$1.8M+17.8%	$1.5M-46.9%	$2.9M+29.9%	$2.2M+12.2%	$2.0M
SG&A Expenses	$7.7M	$7.6M+3.3%	$7.4M-2.8%	$7.6M-14.3%	$8.8M-9.4%	$9.8M+3.2%	$9.5M-33.3%	$14.2M-23.9%	$18.6M-6.5%	$19.9M+16.7%	$17.1M+9.7%	$15.6M+25.3%	$12.4M+7.4%	$11.6M-2.8%	$11.9M-9.9%	$13.2M
Operating Income	-$1.4M	-$2.5M+33.7%	-$3.7M+21.1%	-$4.7M-2.9%	-$4.6M+22.4%	-$5.9M-70.7%	-$3.4M+53.3%	-$7.4M+34.4%	-$11.3M+20.7%	-$14.2M-9.4%	-$13.0M+11.8%	-$14.7M-121.0%	-$6.7M-10.0%	-$6.1M-79.3%	-$3.4M+47.8%	-$6.5M
EBITDA	N/A	-$2.3M+35.0%	-$3.6M+21.1%	-$4.5M-1.8%	-$4.4M+22.0%	-$5.7M-76.9%	-$3.2M+54.5%	-$7.1M+34.5%	-$10.8M+21.1%	-$13.7M-7.6%	-$12.7M+12.1%	-$14.5M-125.9%	-$6.4M-11.1%	-$5.8M-85.7%	-$3.1M+49.4%	-$6.1M
Interest Expense	N/A	N/A	N/A	N/A	$16K+260.0%	-$10K-183.3%	$12K-25.0%	$16K-51.5%	$33K-17.5%	$40K+1233.3%	$3K0.0%	$3K0.0%	$3K-99.7%	$1.1M-4.4%	$1.1M+18.9%	$931K
Income Tax	-$243K	-$244K-144.4%	$550K+380.6%	-$196K-493.9%	-$33K+90.1%	-$332K-146.6%	$713K+2358.6%	$29K-93.7%	$458K+816.0%	$50K+101.2%	-$4.3M	$0	$0	$0	$0+100.0%	-$1.1M
Net Income	$914K	$3K-8.2%	$3K-28.5%	$5K+100.1%	-$5.2M-1.3%	-$5.1M-28.8%	-$4.0M-19.4%	-$3.3M+72.0%	-$11.8M+17.7%	-$14.3M-254.5%	$9.3M+191.3%	-$10.2M-23.9%	-$8.2M-319.6%	$3.7M+168.8%	-$5.4M+25.9%	-$7.3M
EPS (Basic)	N/A	-$1.89+32.3%	-$2.79+73.8%	-$10.63-599.3%	-$1.52+20.8%	-$1.92+16.9%	-$2.31+4.5%	-$2.42	N/A	N/A	N/A	N/A	-$0.85-257.4%	$0.54+141.5%	-$1.30	N/A
EPS (Diluted)	—	-$1.89	-$2.79	-$0.01	-$1.52+20.8%	-$1.92	N/A	N/A	N/A	N/A	N/A	N/A	-$0.85-257.4%	$0.54	-$1.30	N/A
Diluted Shares (Avg)	N/A	2M	1M	455,000	3M+127830.6%	2,653	N/A	N/A	N/A	N/A	N/A	N/A	10M+40.0%	7M	5M	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$6.4M+59.6%	$5.6M+48.1%	$4.3M+22.0%	$5.6M+56.6%	$4.0M+18.4%	$3.8M+9.2%	$3.6M+13.6%	$3.6M+31.1%
Cost of Revenue	$3.8M+50.1%	$3.4M+51.8%	$2.7M+17.7%	$3.5M+57.1%	$2.6M+22.4%	$2.2M-5.2%	$2.3M+36.7%	$2.2M+27.4%
Gross Profit	$2.6M+76.0%	$2.2M+42.7%	$1.6M+29.9%	$2.1M+55.8%	$1.5M+12.1%	$1.5M+40.1%	$1.3M-13.0%	$1.4M+37.5%
R&D Expenses	$597K+0.5%	$545K+32.6%	$557K+30.4%	$575K+13.6%	$594K+26.4%	$411K+0.5%	$427K-29.0%	$506K-5.6%
SG&A Expenses	$2.0M+2.8%	$2.0M+12.1%	$1.8M-5.5%	$1.9M+10.4%	$2.0M-2.2%	$1.8M-15.2%	$1.9M+10.0%	$1.7M+2.6%
Operating Income	-$40K+96.3%	-$351K+46.5%	-$678K+34.2%	-$337K+60.4%	-$1.1M+6.6%	-$656K+53.4%	-$1.0M-22.2%	-$850K+29.6%
EBITDA	-$8K+99.2%	-$318K+49.1%	-$644K+35.5%	-$301K+63.1%	-$1.1M+6.6%	-$625K+54.3%	-$998K-24.9%	-$815K+29.9%
Income Tax	$0+100.0%	$84K-66.1%	-$130K-1544.4%	-$197K-234.0%	-$1K-100.7%	$248K+184.9%	$9K+115.8%	$147K-21.0%
Net Income	-$330K+73.4%	$2.6M-3.3%	-$819K+11.7%	-$534K+12.5%	-$1.2M-8.6%	$2.7M-28.8%	-$928K-7.2%	-$610K+58.9%
EPS (Basic)	-$0.09+88.2%	-$0.33+15.4%	-$0.48+23.8%	-$0.32+45.8%	-$0.76+43.3%	-$0.39-4000.0%	-$0.63+60.4%	-$0.59+89.7%
EPS (Diluted)	-$0.09	-$0.33	-$0.48+23.8%	-$0.32	-$0.76	-$0.39	-$0.63	-$0.59
Diluted Shares (Avg)	4M	N/A	2M+17.0%	2M	2M	N/A	1M	1M

Not reported in any period shown, so not listed: Interest Expense.

SNOA Balance Sheet

SNOA quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$14.0M+1.9%	$13.7M-7.1%	$14.7M-9.2%	$16.2M-13.9%	$18.8M+25.7%	$15.0M+2.9%	$14.6M+0.8%	$14.4M-24.8%	$19.2M-24.6%	$25.5M+84.4%	$13.8M-8.3%	$15.0M-27.6%	$20.8M+65.5%	$12.6M+60.3%	$7.8M
Current Assets	$12.1M-4.3%	$12.6M+0.8%	$12.5M-9.1%	$13.8M-16.0%	$16.4M+26.6%	$13.0M+5.7%	$12.3M-1.7%	$12.5M-23.1%	$16.3M-28.2%	$22.6M+75.7%	$12.9M+33.6%	$9.6M+1.1%	$9.5M-17.3%	$11.5M+65.7%	$7.0M
Cash & Equivalents	$2.4M-55.4%	$5.4M+71.8%	$3.1M-18.1%	$3.8M-48.4%	$7.4M+75.3%	$4.2M+14.3%	$3.7M+0.1%	$3.7M-63.4%	$10.1M-42.4%	$17.5M+133.8%	$7.5M+21.7%	$6.1M+12.0%	$5.5M-30.6%	$7.9M+135.8%	$3.4M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.7M+25.2%	$2.9M+7.2%	$2.7M-4.9%	$2.9M+7.3%	$2.7M+5.3%	$2.5M+16.0%	$2.2M-36.0%	$3.4M+19.0%	$2.9M+29.0%	$2.2M+39.2%	$1.6M+13.8%	$1.4M+28.9%	$1.1M+9.7%	$992K+4.1%	$953K
Accounts Receivable	$2.5M+13.2%	$2.2M-23.0%	$2.9M+12.7%	$2.6M+6.9%	$2.4M-14.2%	$2.8M-29.4%	$4.0M+14.1%	$3.5M+126.5%	$1.5M-27.1%	$2.1M+39.8%	$1.5M-0.6%	$1.5M-15.3%	$1.8M+4.9%	$1.7M-20.6%	$2.2M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$4.5M-55.3%	$10.2M	$0	$0
Total Liabilities	$10.9M+17.1%	$9.3M+7.9%	$8.6M+4.2%	$8.3M-18.7%	$10.1M+5.4%	$9.6M+7.7%	$8.9M+125.7%	$4.0M+2.0%	$3.9M-3.7%	$4.0M+10.0%	$3.7M+22.3%	$3.0M-65.7%	$8.7M+2.9%	$8.5M-2.5%	$8.7M
Current Liabilities	$4.8M+18.0%	$4.1M+10.1%	$3.7M+0.1%	$3.7M-36.1%	$5.8M+42.7%	$4.1M-13.8%	$4.7M+31.7%	$3.6M+10.1%	$3.3M-0.8%	$3.3M-7.4%	$3.6M+37.6%	$2.6M-65.9%	$7.6M+47.7%	$5.1M+8.0%	$4.7M
Non-Current Liabilities	$6.0M+16.3%	$5.2M+6.2%	$4.9M+7.6%	$4.5M+4.8%	$4.3M-21.9%	$5.5M+31.8%	$4.2M+1043.5%	$368K-40.5%	$619K-16.4%	$740K+560.7%	$112K-72.9%	$413K-64.3%	$1.2M-65.6%	$3.4M-15.2%	$4.0M
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$1.3M	$0-100.0%	$12K-62.5%	$32K-28.9%	$45K	$0	$0-100.0%	$4K-99.4%	$676K-62.9%	$1.8M
Total Equity	$3.1M-29.8%	$4.4M-28.1%	$6.1M-23.1%	$8.0M-8.3%	$8.7M+62.2%	$5.4M-4.6%	$5.6M-27.6%	$7.8M-49.3%	$15.3M-28.5%	$21.4M+111.4%	$10.1M-15.9%	$12.1M-0.1%	$12.1M+195.6%	$4.1M+570.2%	-$868K
Retained Earnings	-$201.0M-1.6%	-$197.8M-1.8%	-$194.3M-2.6%	-$189.5M-2.8%	-$184.4M-2.8%	-$179.3M-2.3%	-$175.3M-3.6%	-$169.2M-7.5%	-$157.4M-10.0%	-$143.1M+6.1%	-$152.4M-7.1%	-$142.2M-6.1%	-$134.0M+2.7%	-$137.7M-4.1%	-$132.3M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$18.1M+24.1%	$14.0M+1.9%	$13.6M-0.3%	$13.9M+1.2%	$14.6M+6.7%	$13.7M-7.1%	$13.7M-6.5%	$13.7M+0.4%
Current Assets	$16.3M+24.1%	$12.1M-4.3%	$12.1M-1.9%	$12.5M+2.3%	$13.1M+9.9%	$12.6M+0.8%	$12.4M-1.0%	$12.2M+6.1%
Cash & Equivalents	$5.3M+48.1%	$2.4M-55.4%	$2.6M-51.1%	$3.0M-25.6%	$3.6M+39.2%	$5.4M+71.8%	$5.2M+117.6%	$4.1M+90.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.8M-0.4%	$3.7M+25.2%	$3.7M+17.8%	$3.6M+28.1%	$3.8M+43.0%	$2.9M+7.2%	$3.1M+6.4%	$2.8M+12.9%
Accounts Receivable	$3.2M+22.3%	$2.5M+13.2%	$2.4M-1.0%	$2.7M-14.4%	$2.6M-19.9%	$2.2M-23.0%	$2.4M-16.4%	$3.2M+42.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$11.5M+9.3%	$10.9M+17.1%	$10.2M+15.8%	$10.1M+20.8%	$10.5M+21.2%	$9.3M+7.9%	$8.8M+11.0%	$8.3M+4.7%
Current Liabilities	$5.4M+12.4%	$4.8M+18.0%	$4.2M+13.9%	$4.3M+30.6%	$4.8M+29.2%	$4.1M+10.1%	$3.7M+20.5%	$3.3M+2.2%
Non-Current Liabilities	$6.1M+6.6%	$6.0M+16.3%	$6.0M+17.3%	$5.7M+14.4%	$5.7M+15.0%	$5.2M+6.2%	$5.1M+5.0%	$5.0M+6.4%
Total Equity	$6.6M+62.6%	$3.1M-29.8%	$3.4M-29.5%	$3.8M-29.2%	$4.1M-18.5%	$4.4M-28.1%	$4.9M-27.2%	$5.4M-5.7%
Retained Earnings	-$201.3M-1.1%	-$201.0M-1.6%	-$200.4M-1.7%	-$199.6M-1.8%	-$199.0M-1.8%	-$197.8M-1.8%	-$197.0M-1.9%	-$196.1M-1.9%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

SNOA Cash Flow Statement

SNOA quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$2.6M	-$3.9M-4369.3%	-$88K+96.3%	-$2.4M+61.0%	-$6.2M-44.8%	-$4.2M-25.8%	-$3.4M+26.4%	-$4.6M+60.8%	-$11.7M+5.8%	-$12.4M-52.3%	-$8.2M+6.6%	-$8.7M-30.7%	-$6.7M-36.9%	-$4.9M-525.2%	$1.1M+128.5%	-$4.0M
Depreciation & Amortization	N/A	$139K+0.7%	$138K-21.6%	$176K+40.8%	$125K-32.8%	$186K-18.1%	$227K-27.2%	$312K-31.1%	$453K-7.6%	$490K+97.6%	$248K+1.6%	$244K-3.6%	$253K-10.9%	$284K+6.0%	$268K-17.8%	$326K
Stock-Based Compensation	N/A	$255K+13.8%	$224K-56.6%	$516K-22.9%	$669K+75.1%	$382K+3.0%	$371K-55.8%	$839K-48.7%	$1.6M-34.6%	$2.5M+16.6%	$2.1M-0.3%	$2.2M+21.5%	$1.8M+22.1%	$1.5M-9.4%	$1.6M-42.8%	$2.8M
Capital Expenditures	$88K	$192K+140.0%	$80K+3900.0%	$2K-99.3%	$269K+96.4%	$137K-23.5%	$179K-13.1%	$206K+106.0%	$100K-46.5%	$187K-52.5%	$394K+14.2%	$345K+148.2%	$139K-72.4%	$504K+96.1%	$257K-23.5%	$336K
Free Cash Flow	-$2.7M	-$4.1M-2355.4%	-$168K+93.0%	-$2.4M+62.6%	-$6.4M-46.4%	-$4.4M-23.3%	-$3.6M+25.8%	-$4.8M+59.4%	-$11.8M+6.4%	-$12.6M-47.5%	-$8.6M+5.8%	-$9.1M-33.0%	-$6.8M-26.7%	-$5.4M-704.0%	$893K+120.4%	-$4.4M
Investing Cash Flow	-$88K	-$192K-140.0%	-$80K-3900.0%	-$2K+99.2%	-$258K-160.6%	-$99K-125.5%	$388K-89.4%	$3.6M+2881.7%	-$131K	N/A	N/A	N/A	N/A	N/A	-$370K-2.8%	-$360K
Financing Cash Flow	$4.0M	$477K-84.3%	$3.0M+80.8%	$1.7M-32.7%	$2.5M-66.3%	$7.4M+123.6%	$3.3M+221.5%	$1.0M-81.3%	$5.5M	N/A	N/A	N/A	N/A	N/A	$3.8M+8.7%	$3.4M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	-$649K+67.8%	-$519K-446.3%	-$764K-235.2%	-$635K-279.4%	-$2.0M-120.9%	-$95K-162.5%	$565K+151.2%	$354K+128.8%
Depreciation & Amortization	$32K-11.1%	$33K+6.5%	$34K+3.0%	$36K+2.9%	$36K-7.7%	$31K-24.4%	$33K-26.7%	$35K-22.2%
Stock-Based Compensation	$58K+1.8%	N/A	$24K+84.6%	$39K+178.6%	$57K-46.7%	N/A	$13K-90.7%	$14K-89.2%
Capital Expenditures	$2K-98.1%	$29K-38.3%	$47K+2250.0%	$10K-61.5%	$106K+2020.0%	$47K+161.1%	$2K+100.0%	$26K+1200.0%
Free Cash Flow	-$651K+69.3%	-$548K-285.9%	-$811K-244.0%	-$645K-296.6%	-$2.1M-131.3%	-$142K-206.0%	$563K+151.0%	$328K+126.6%
Investing Cash Flow	-$2K+98.1%	-$29K+38.3%	-$47K-2250.0%	-$10K+61.5%	-$106K-2020.0%	-$47K-361.1%	-$2K-100.0%	-$26K-1200.0%
Financing Cash Flow	$3.5M+6055.2%	$387K+59.9%	$210K-70.3%	-$62K-104.3%	-$58K-109.1%	$242K-61.1%	$708K-46.3%	$1.4M+1219.4%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SNOA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SNOA quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	38.0%-0.3pp	38.3%+1.0pp	37.3%+3.5pp	33.7%+2.1pp	31.6%-3.6pp	35.2%-10.1pp	45.3%-1.5pp	46.8%+2.9pp	43.9%-0.3pp	44.2%+15.9pp	28.3%-24.3pp	52.6%-8.8pp	61.4%-8.1pp	69.5%+1.1pp	68.4%
Operating Margin	-12.6%+13.4pp	-26.0%+10.9pp	-36.9%-2.5pp	-34.4%+12.2pp	-46.6%-28.1pp	-18.5%+22.7pp	-41.2%+18.1pp	-59.4%+25.8pp	-85.2%	-101.2%	-157.1%	-48.1%-3.8pp	-44.3%-22.4pp	-21.8%+28.9pp	-50.7%
Net Margin	0.0%0.0pp	0.0%0.0pp	0.0%+38.9pp	-38.8%+1.5pp	-40.3%-19.1pp	-21.2%-2.7pp	-18.4%+43.7pp	-62.2%+23.8pp	-86.0%-158.3pp	72.3%	-108.5%	-59.2%-86.5pp	27.3%+62.5pp	-35.1%+22.4pp	-57.5%
Return on Equity	0.1%0.0pp	0.1%0.0pp	0.1%+64.7pp	-64.6%-6.1pp	-58.5%+15.2pp	-73.7%-14.8pp	-58.8%+93.0pp	-151.8%-58.4pp	-93.5%-136.8pp	43.3%+143.5pp	-100.2%-32.2pp	-68.0%-99.0pp	31.0%+164.0pp	-133.1%	N/A
Return on Assets	0.0%0.0pp	0.0%0.0pp	0.0%+31.8pp	-31.7%-4.8pp	-27.0%-0.6pp	-26.4%-3.6pp	-22.7%+58.9pp	-81.7%-7.1pp	-74.6%-111.0pp	36.4%+110.0pp	-73.6%-19.1pp	-54.5%-72.5pp	18.0%+61.2pp	-43.2%+50.3pp	-93.5%
Current Ratio	2.50-0.6x	3.09-0.3x	3.37-0.3x	3.71+0.9x	2.82-0.4x	3.18+0.6x	2.60-0.9x	3.48-1.5x	4.98-1.9x	6.89+3.3x	3.63-0.1x	3.74+2.5x	1.26-1.0x	2.25+0.8x	1.47
Debt-to-Equity	3.51+1.4x	2.10+0.7x	1.40+0.4x	1.03+1.0x	0.00-0.2x	0.24+0.2x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00-0.2x	0.17	N/A
Asset Turnover	1.40+0.4x	1.04+0.2x	0.860.0x	0.82+0.1x	0.67-0.6x	1.240.0x	1.23-0.1x	1.31+0.4x	0.87+0.4x	0.50-0.2x	0.68-0.2x	0.92+0.3x	0.66-0.6x	1.23-0.4x	1.63
FCF Margin	-21.1%-19.9pp	-1.2%+17.7pp	-18.9%+29.5pp	-48.4%-13.7pp	-34.7%-15.6pp	-19.1%+7.7pp	-26.8%+35.5pp	-62.3%+13.5pp	-75.8%-9.1pp	-66.8%+30.3pp	-97.0%-47.7pp	-49.3%-9.9pp	-39.5%-45.2pp	5.8%+40.1pp	-34.3%

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	40.2%+3.8pp	39.2%-1.5pp	37.9%+2.3pp	37.8%-0.2pp	36.5%-2.1pp	40.7%+9.0pp	35.6%-10.9pp	38.0%+1.8pp
Operating Margin	-0.6%+26.7pp	-6.3%+11.2pp	-15.6%+13.3pp	-6.0%+17.7pp	-27.3%+7.3pp	-17.5%+23.5pp	-28.9%-2.0pp	-23.8%+20.5pp
Net Margin	-5.1%+25.8pp	46.7%-24.8pp	-18.8%+7.2pp	-9.5%+7.5pp	-30.9%+2.8pp	71.5%	-26.0%+1.6pp	-17.0%+37.3pp
Return on Equity	-5.0%+25.6pp	83.9%+23.1pp	-23.9%-4.8pp	-14.1%-2.7pp	-30.6%-7.6pp	60.9%-0.6pp	-19.1%-6.1pp	-11.4%+14.8pp
Return on Assets	-1.8%+6.7pp	18.6%-1.0pp	-6.0%+0.8pp	-3.9%+0.6pp	-8.5%-0.1pp	19.6%-6.0pp	-6.8%-0.9pp	-4.5%+6.4pp
Current Ratio	2.99+0.3x	2.50-0.6x	2.88-0.5x	2.89-0.8x	2.70-0.5x	3.09-0.3x	3.34-0.7x	3.69+0.1x
Debt-to-Equity	1.75-0.9x	3.51+1.4x	2.97+1.2x	2.66+1.1x	2.60+0.8x	2.10+0.7x	1.81+0.6x	1.56+0.2x
Asset Turnover	0.35+0.1x	0.40+0.1x	0.32+0.1x	0.40+0.1x	0.280.0x	0.270.0x	0.260.0x	0.26+0.1x
FCF Margin	-10.2%+42.7pp	-9.8%-6.1pp	-18.6%-34.5pp	-11.5%-20.7pp	-52.8%-25.8pp	-3.8%-7.7pp	15.8%+51.0pp	9.2%+54.3pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Sonoma Pharmaceuticals, Inc. SNOA	FY2026	$19.5M	$3K	0.0%	$5.7M	40/100
Evoke Pharma, Inc. EVOK	FY2024	$10.2M	-$5.4M	-52.2%	$18.9M	58/100
Sunshine Biopharma Inc. SBFM	FY2025	$36.3M	-$6.0M	-16.5%	$1.2M	59/100
Biofrontera Inc. BFRI	FY2025	$41.7M	-$10.5M	-25.3%	$13.7M	39/100
cbdMD, Inc. YCBD	FY2025	$19.2M	-$2.0M	-10.6%	$4.0M	38/100

Where Sonoma Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Sonoma Pharmaceuticals, Inc.'s annual revenue?

Sonoma Pharmaceuticals, Inc. (SNOA) reported $19.5M in total revenue for fiscal year 2026. This represents a 36.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sonoma Pharmaceuticals, Inc.'s revenue growing?

Sonoma Pharmaceuticals, Inc. (SNOA) revenue grew by 36.7% year-over-year, from $14.3M to $19.5M in fiscal year 2026.

Is Sonoma Pharmaceuticals, Inc. profitable?

Yes, Sonoma Pharmaceuticals, Inc. (SNOA) reported a net income of $3K in fiscal year 2026, with a net profit margin of 0.0%.

What is Sonoma Pharmaceuticals, Inc.'s EBITDA?

Sonoma Pharmaceuticals, Inc. (SNOA) had EBITDA of -$2.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Sonoma Pharmaceuticals, Inc.'s gross margin?

Sonoma Pharmaceuticals, Inc. (SNOA) had a gross margin of 38.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Sonoma Pharmaceuticals, Inc.'s operating margin?

Sonoma Pharmaceuticals, Inc. (SNOA) had an operating margin of -12.6% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Sonoma Pharmaceuticals, Inc.'s net profit margin?

Sonoma Pharmaceuticals, Inc. (SNOA) had a net profit margin of 0.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Sonoma Pharmaceuticals, Inc.'s return on equity (ROE)?

Sonoma Pharmaceuticals, Inc. (SNOA) has a return on equity of 0.1% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Sonoma Pharmaceuticals, Inc.'s free cash flow?

Sonoma Pharmaceuticals, Inc. (SNOA) recorded an outflow of $4.1M in free cash flow during fiscal year 2026. This represents a -2355.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sonoma Pharmaceuticals, Inc.'s operating cash flow?

Sonoma Pharmaceuticals, Inc. (SNOA) recorded an outflow of $3.9M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are Sonoma Pharmaceuticals, Inc.'s total assets?

Sonoma Pharmaceuticals, Inc. (SNOA) had $14.0M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Sonoma Pharmaceuticals, Inc.'s capital expenditures?

Sonoma Pharmaceuticals, Inc. (SNOA) invested $192K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Sonoma Pharmaceuticals, Inc. spend on research and development?

Sonoma Pharmaceuticals, Inc. (SNOA) invested $2.3M in research and development during fiscal year 2026.

How many shares does Sonoma Pharmaceuticals, Inc. have outstanding?

Sonoma Pharmaceuticals, Inc. (SNOA) had 5M shares outstanding as of fiscal year 2026.

What is Sonoma Pharmaceuticals, Inc.'s current ratio?

Sonoma Pharmaceuticals, Inc. (SNOA) had a current ratio of 2.50 as of fiscal year 2026, which is generally considered healthy.

What is Sonoma Pharmaceuticals, Inc.'s debt-to-equity ratio?

Sonoma Pharmaceuticals, Inc. (SNOA) had a debt-to-equity ratio of 3.51 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sonoma Pharmaceuticals, Inc.'s return on assets (ROA)?

Sonoma Pharmaceuticals, Inc. (SNOA) had a return on assets of 0.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Sonoma Pharmaceuticals, Inc.'s P/E ratio?

Sonoma Pharmaceuticals, Inc. (SNOA) trades at 6.2x earnings, its market capitalization divided by net income of $914K net income, trailing 12 months to June 30, 2026. The market capitalization is $5.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Sonoma Pharmaceuticals, Inc.'s price-to-sales ratio?

Sonoma Pharmaceuticals, Inc. (SNOA) trades at 0.3x sales, its market capitalization divided by revenue of $21.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $5.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Sonoma Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, Sonoma Pharmaceuticals, Inc. (SNOA) held $2.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.9M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Sonoma Pharmaceuticals, Inc.'s Altman Z-Score?

Sonoma Pharmaceuticals, Inc. (SNOA) has an Altman Z-Score of -18.40, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Sonoma Pharmaceuticals, Inc.'s Piotroski F-Score?

Sonoma Pharmaceuticals, Inc. (SNOA) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sonoma Pharmaceuticals, Inc.'s earnings high quality?

Sonoma Pharmaceuticals, Inc. (SNOA) reported $3K of net income while operations used $3.9M of cash. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Sonoma Pharmaceuticals, Inc.?

Sonoma Pharmaceuticals, Inc. (SNOA) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.